Identifying Polymorphism with in-situ Raman Spectroscopy at Screening Scale

  • Crystallization
  • 8 March 2022

About the webinar

This webinar was hosted by Scientific Update and brought to you by joining forces with Tornado Spectral Systems.

Polymorphism in API play a crucial role in final particle properties such as bioavailability, morphology, and dissolution rate with direct effect on important downstream decisions. Therefore detecting, identifying, and controlling polymorphism is an area of great interest. Several methods can be used to detect and differentiate different polymorphs such as FTIR, XRPD and single crystal; however, Raman spectroscopy can be used in situ to monitor real time polymorphic transformations. Through measurement of the Raman spectra of solids in suspension during a crystallization process, it is possible to track the formation and conversion of polymorphs in real time giving important information in crystallization development. Additionally, in-situ measurements such as microscopy can be used to observe problems such as oiling out and agglomeration. By identifying conditions that cause unwanted changes, steps can be taken to designing, prevent or reverse these changes by improving the reliability and stability of a crystallization process.

This webinar is presented by Dr. Thomas Kendall, Application Specialist at Technobis Crystallization Systems and Mark Kemper, Director of Application Development at Tornado Spectral Systems.

Discover how the Crystalline RR gives the user access to real time Raman spectroscopy, in combination with a sophisticated parallel crystallizer with turbidity measurement and help your projects succeed!

You can download the webinar presentation slides from our Publications section here.

Presenter

Thomas Kendall

Application Specialist at Technobis

Thomas has 9 years of experience in solid form and crystallization development in the pharmaceutical sector. He earned his PhD in Chemical Engineering with CMAC at the University of Strathclyde, investigating nucleation mechanisms in pharma systems. He previously worked for Pharmorphix (part of Johnson Matthey) as a solid form scientist investigating customer compounds in pharma and agro sector.  With extensive experience in polymorph, salt, and co-crystal screening, as well as crystallization development using process analytical technologies, experiments, and modelling software up to kilogram scale, Thomas has authored several patents, webinars, and a book chapter on solid form and crystallization development.